ADC Therapeutics (ADCT) Fundamental Analysis: Revenue, Earnings & Valuation

4.94 / 10

Netural

Fundamental score is 4.9/10, indicating moderate quality. Strengths include high inventory turnover, low cost‑of‑sales ratio, solid interest coverage and double‑digit revenue growth. Weak points are a modest long‑term debt‑to‑working‑capital ratio and low PB‑ROE. Overall, fundamentals are selective.

Analysis Checks(8/10)

Revenue-MV

Value-0.93

Score2/3

Weight20.13%

1M Return4.88%

Total operating revenue (YoY growth rate %)

Value14.85

Score2/3

Weight0.44%

1M Return0.13%

Inventory turnover ratio

Value1.80

Score3/3

Weight-3.12%

1M Return-0.93%

Current liabilities / Total liabilities (%)

Value13.78

Score3/3

Weight5.90%

1M Return1.67%

PB-ROE

Value0.02

Score1/3

Weight25.65%

1M Return7.56%

Long-term debt to working capital ratio (%)

Value1.86

Score1/3

Weight-2.13%

1M Return-0.65%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight-3.68%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value14.85

Score2/3

Weight0.18%

1M Return0.05%

Cost of sales ratio (%)

Value7.13

Score3/3

Weight0.92%

1M Return0.26%

Asset-MV

Value-0.55

Score3/3

Weight55.72%

1M Return11.61%

Is ADCT fundamentally strong?

ADCT scores 4.94/10 on fundamentals and holds a Fair valuation at present. Backed by its 0.00% ROE, -175.31% net margin, -3.37 P/E ratio, -2.58 P/B ratio, and 30.86% earnings growth, these metrics solidify its Netural investment rating.